Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease by unknown
Korish and Arafah BMC Complementary and Alternative Medicine 2013, 13:264
http://www.biomedcentral.com/1472-6882/13/264RESEARCH ARTICLE Open AccessCamel milk ameliorates steatohepatitis, insulin
resistance and lipid peroxidation in experimental
non-alcoholic fatty liver disease
Aida A Korish1* and Maha M Arafah2Abstract
Background: Camel milk (CM) is gaining increasing recognition due to its beneficial effects in the control and
prevention of multiple health problems. The current study aimed to investigate the effects of CM on the hepatic
biochemical and cellular alterations induced by a high-fat, cholesterol-rich diet (HCD), specifically, non-alcoholic
fatty liver disease (NAFLD).
Methods: Seventy male Wistar rats were divided into four groups: the Control (C) Group fed a standard diet; the
Control + camel milk (CCM) Group fed a standard diet and CM, the Cholesterol (Ch) Group fed a HCD with no CM,
and the Cholesterol + camel milk (ChM) Group fed a HCD and CM. The following parameters were investigated in
the studied groups; basal, weekly random and final fasting blood glucose levels, intraperitoneal glucose tolerance
test (GTT) and insulin tolerance test (ITT), serum insulin, serum lipids, liver functions, lipid peroxidation products, the
antioxidant activity of catalase (CAT) and the levels of reduced glutathione (GSH). In addition, HOMA-IR as an index
of insulin resistance (IR) and the histopathology of the hepatic tissue were assessed.
Results: The Ch Group developed features similar to those of non-alcoholic steatohepatitis (NASH), characterized
by hepatic steatosis; inflammatory cellular infiltration in liver tissue; altered liver functions; and increased total
cholesterol, triglycerides, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, atherogenic
index (AI), blood glucose, IR, and malondialdehyde (MDA) levels. Additionally, feeding the HCD to animals in the Ch
Group decreased CAT activity and the GSH and high-density lipoprotein (HDL) cholesterol levels. Camel milk intake
for eight weeks decreased hepatic fat accumulation and inflammatory cellular infiltration, preserved liver function,
increased the GSH levels and CAT activity, decreased the MDA levels, and ameliorated the changes in the lipid
profile, AI, and IR in animals from the ChM Group.
Conclusions: CM has a unique composition that is rich in minerals; vitamins, insulin and insulin-like protein, and
it increased HDL-cholesterol and ameliorated the biochemical and cellular features of NAFLD in rats that received
a HCD. The antioxidant effect of CM is a likely mechanism for the altered metabolism and absorption of HCD in
the presence of CM. Regular consumption of CM could provide a natural way to protect against NAFLD induced
by a high-fat diet.
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Fatty liver refers to a large spectrum of diseases character-
ized by excessive fat accumulation in the liver, which could
be alcoholic or non-alcoholic in origin. Non-alcoholic fatty
liver disease (NAFLD) is clinically important because it
affects 25% of the population, with widespread pathological
changes in the liver that range from simple non-
progressive steatosis to non-alcoholic steatohepatitis
(NASH). This can progress to cirrhosis, hepatocellular
carcinoma, and liver failure with increased hepatic-related
mortality [1,2].
Clinically, NASH is linked to visceral obesity, insulin
resistance (IR), dyslipidemia, and type II diabetes mellitus.
The clustering of these metabolic risk factors, identified
as ‘insulin resistance syndrome,’ increases free fatty acid
(FFA) release from adipose tissue, which results from
decreased insulin-mediated repression of lipolysis, and
induces NASH [3].
The relationship between IR and NASH is reciprocal,
and they potentiate each other; therefore, scientists
consider NASH to be the liver manifestation of meta-
bolic syndrome [4]. Diet-induced obesity predisposes
individuals to a spectrum of disorders, including metabolic
syndrome, hepatic steatosis, and NASH. For that reason, a
high-fat, cholesterol-rich diet (HCD) is commonly used in
the experimental induction of hyperlipidemia and NAFLD
[5]. Conversely, several plants, such as ginger, cinnamon,
licorice, berries, plant leaves, and herb roots, in addition
to animal products such as bones, hooves, skins, feathers,
and milk, have long been used in traditional and alter-
native medicine. These substances are increasingly valued
as raw materials in the preparation of modern medicine
and herbal preparations [6].
According to the World Health Organization (WHO),
approximately 80% of the population in some African
and Asian countries and 38% in the Americas depend
primarily on complementary and alternative medicine
for the prevention, protection and treatment of diseases
[7,8].
Camel milk (CM) is used in hot and arid regions as an
essential nutritional source, and its high energy and vita-
min contents are known to help immune-deficient patients
as well as those recovering from diseases [9-11]. Oral
CM is well tolerated by lactase-deficient children who are
allergic to cow milk [12], and it shows protective effects
against heavy metal toxicity [13] and viral and bacterial
infections [14]. Additionally, Indians used CM for the
treatment of multiple acute and chronic health problems,
including asthma, anemia, jaundice, and spleen problems
[15]. Interestingly, the low prevalence of diabetes in the
Raica community was attributed to the regular consump-
tion of CM [16]. This was further supported by the better
glycemic control in diabetic patients and animals receiving
CM [17,18].Recent studies have shown that CM has antihypertensive,
anti-cancerous, hepatoprotective, and hypocholesterolemic
effects [19-22]. However, the effects of CM on HCD-
induced hepatic biochemical and structural changes,
oxidative-antioxidative balance and glucose homeostasis
have not been investigated. The reported health benefits
of CM justified the great public concern and stimulated
our interest to investigate its effects on NAFLD because
this conditions is one of the obesity-associated disorders
that is currently widely prevalent. We hypothesized that
acquiring healthy dietary habits and the regular consump-
tion of natural products such as CM can protect against
the metabolic and cellular ailments induced by a HCD,
which is extensively consumed, for example, fast food
meals. The present study will help the establishment of
scientific background knowledge regarding CM as a
natural food with potential therapeutic and protective
effects against one or more currently prevalent health
problems associated with dyslipidemia and IR.
Methods
Animals and experimental groups
Male Wistar rats, 6 to 8 wk old (weighing 270–325 g),
were obtained from the Animal Care Unit of the College of
Medicine, King Saud University (KSU). The Institutional
Review Board (IRB) (formerly Ethical Committee) of the
College of Medicine, KSU, approved the study protocol,
and all of the animal handling procedures adhered to the
guidelines of the College of Medicine Research Center
and and the ‘Guide for the Care and Use of Laboratory
Animals’, as declared by the Committee on Care and
Use of Laboratory Animals of the Institute of Laboratory
Animal Resources, National Research Council, USA. The
animals were housed five per cage in a 21°C temperature-
controlled facility with a 12-h light/dark cycle and free
access to rat chow and water ad libitum. After one
week of acclimatization, animals were randomized into
four experimental groups:
Control (C) Group (n = 10): normal rats fed standard
rat chow.
Control + CM (CCM) Group (n = 20): normal rats fed
standard rat chow and CM.
Cholesterol (Ch) Group (n = 20): rats fed a HCD.
Cholesterol + CM (ChM) Group (n = 20): rats fed a
HCD and CM.
Body weight was recorded at the beginning and the
end of the study in all the experimental groups.
Induction of hyperlipidemia
Commercial rat chow (Grain Silos & Flour Mills
Organization Riyadh Branch, Riyadh, K.S.A) that con-
tains 20% crude protein; 4% fat; 3.5% crude fiber; 6%
ash, 0.5% salt, 1% calcium, 0.6% phosphorous, 20 IU/g
vitamin A, 20 IU/g vitamin D, 20 IU/kg vitamin E, and
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selenium, and zinc was used in the C and CCM Groups. A
high-fat, cholesterol-rich diet (HCD), in which 42% of the
energy is derived from fats, was prepared by the addition
of 1.5% cholesterol (Sigma Aldrich, USA) and 8% coconut
oil to the basal diet [5]. The HCD was prepared every
2 days, kept at 4°C, and given to rats in the Ch and
ChM Groups for 8 weeks.
Camel milk administration
Camel milk was collected daily from a private camel
farm in the middle of Riyadh, Saudi Arabia, transported
to the laboratory in screw-capped bottles in cool boxes,
and administered orally at a rate of 250 ml/cage/day (i.e.,
approximately 50 ml/rat/day) for 8 weeks to the animals
in the CCM and ChM Groups.
To standardize the quality of the milk used, the milked
camel and its diet were kept unchanged throughout the
study. A pilot study was conducted before the start of
the experimental period to estimate the average volume
of CM that can be consumed per rat per day, which was
found to be approximately 50 ml/24 hours.
Blood glucose
Basal, weekly random and final fasting blood glucose
levels were recorded using a drop of blood from the tail
vein and an Accu-Check monitor (Roche Diagnostics,
West Sussex, UK).
Intraperitoneal glucose tolerance test (GTT) and insulin
tolerance test (ITT)
To investigate the effects of CM on glucose homeostasis
and insulin sensitivity in animals on normal rat chow
and HCD, ten rats in each group were subjected to an
i.p. GTT and an insulin tolerance test (ITT) during the
last week of the study. Before the GTT, rats were fasted
overnight but allowed free access to water. Baseline (t = 0)
blood samples were taken to measure fasting blood
glucose (FBG) before i.p. injection of D (+) - glucose (1
g/kg) dissolved in 2 ml of distilled water, and the blood
glucose level was recorded after 15, 30, 60, 90, 120,
and 150 minutes with an Accu–Check monitor (Roche
Diagnostics, West Sussex, UK) using a drop of blood
from the tail vein. The ITT was performed in overnight-
fasted animals by an i.p. injection of insulin (0.75 IU/kg)
[23], and the blood glucose level was checked after 0,
4, 8, 12, and 16 minutes. The values are presented as
percentages of the initial blood glucose level.
Blood and tissue sampling
After eight weeks, the animals were fasted overnight,
and blood samples were collected from the retro-orbital
sinus into plain test tubes under Nembutal anesthesia
(50 mg/kg, i.p.) [24]. Serum was separated and storedat −80°C for biochemical analysis. Animals were sacrificed,
and the livers were isolated, macroscopically examined,
and weighed. A small fragment of the liver tissue was
frozen in liquid nitrogen for the measurement of oxidative
stress markers. The remaining liver tissue was immersed
in 10% neutral-buffered formalin and reserved for
histopathological examination. The frozen liver tissue was
homogenized with Ultra Turax Homogenizer (Janken
Kunkel IKa-Werk, Staufen, Germany) in 50 mM phos-
phate buffer, pH 6–7, containing 1 mM EDTA at
10,000 xg for 15 min at 4°C.
Biochemical analysis
Serum insulin
Insulin was measured using the rat insulin enzyme im-
munoassay kit (EIA), Spi-Bio, Montigny le Bretonneux,
France, according to the manufacturer’s instructions and
as reported previously [25].
Serum lipids
Serum lipids were determined using colorimetric kits from
United Diagnostics Industry, Riyadh, KSA, according to
the manufacturer’s instructions [26]. The atherogenic
index (AI) was calculated as total cholesterol [TC] – high-
density lipoprotein cholesterol [HDL-C]/ HDL-C [27].
Liver function tests
The serum transaminases (AST and ALT), alkaline phos-
phatase (AP), gamma glutamyl transpeptidase (GAMA-
GT), total protein, and albumin concentrations were
measured using colorimetric kits from United Diagnos-
tics Industry, Riyadh, KSA.
Lipid peroxidation products
Serum and liver tissue malondialdehyde (MDA) levels
were measured as thiobarbituric acid reactive substances
(TBARS) with a specific EIA kit (Cayman Chemical,
Ann Arbor, MI, USA) at 530–540 nm [28].
Catalase (CAT) activity
A commercial kit produced by Cayman Chemical, Ann
Arbor, MI, USA, was used to measure the antioxidant
CATactivity in serum and liver homogenates. The method
is based on the reaction of the enzyme with methanol in
the presence of an optimal concentration of H2O2. The
enzyme activity was defined as nanomoles of hydrogen
peroxide consumed per minute [29].
Reduced glutathione (GSH)
Liver GSH was assayed according to Ellman’s method
[30] using a glutathione assay kit (Cayman Chemical,
Ann Arbor, MI, USA, Catalog No, 703002).
Figure 1 The changes in body weight (A), liver weight and liver
to body weight ratio (B) in the control and the high-fat diet
groups and the effect of camel milk intake at the end of the
study. CCM; control + milk group, Ch; cholesterol group, ChM;
cholesterol + milk group. Values are presented as the mean ± SD.
† p < 0.05 versus control, ‡ p < 0.05 versus CCM, § p < 0.05 versus Ch,
¶ p < 0.05 versus ChM.
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The homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated as [fasting blood glucose
(mg/dl) x fasting serum insulin (mU/l) /405] [31].
Histopathological examination
The fixed liver tissue samples were embedded in paraffin
and cut into 3–5 μm sections and stained with
hematoxylin and eosin (H&E). The histopathology of
the hepatic tissue was studied using an Olympus BX51
microscope and a DP72 Camera (12 MG Pixel) to assess
the presence of steatosis and inflammation. The fat ac-
cumulation pattern was classified as microvesicular,
macrovesicular, or mixed, and the degree of hepatocyte
involvement was graded as Grade 0: no fat in the liver,
Grade 1 (mild): < 23%, Grade 2 (moderate) < 33-66%, and
Grade 3 (severe): > 66% [1]. The NAFLD activity score
(NAC) classification included non-steatohepatitis, border-
line, zone 3 steatohepatitis, and definite steatohepatitis.
The scores of each component of NAS were as follows:
steatosis (0–3), lobular inflammation (0–3), ballooning
(0–2) and fibrosis (0–2). A score of ≤ 4 indicates border-
line steatohepatitis and > 5 is definite steatohepatitis [32].
Statistical analysis
The results are presented as the mean ± SD and were
statistically analyzed with SPSS for Windows version
18.00. Comparisons between all groups were carried out
by ANOVA, and when significant, the post hoc LSD test
was used to assess the different groups. The results were
considered significant when p < 0.05.
Results
Body weight
After 8 weeks of HCD administration, the Ch Group
exhibited a significant increase in body weight compared
with the C Group fed standard rat chow (p < 0.001),
(Figure 1A). Camel milk significantly decreased the body
weight of the ChM Group in comparison with the Ch
Group (p < 0.013). Likewise, Figure 1A shows that the
percentage increase in body weight at the end of the
study was significantly higher in the Ch Group compared
with the C Group (p < 0.01), but that the ChM Group’s
weight increase was comparable with that of the C Group
(p > 0.05). There was no significant difference in weight
gain between the CCM and C Groups (p > 0.05).
Liver weight and liver: body mass ratio (LBR)
Liver weight and LBR were significantly higher in the Ch
Group in comparison with the C Group (p < 0.001 for
both) (Figure 1B). Adding CM to the diet of the ChM
Group resulted in a significant decrease in the liver
weight and LBR compared with the Ch Group (p < 0.001
for each). In contrast, CM ingestion in the CCM Groupdid not affect their liver weight or LBR compared with
the C Group (p > 0.05).Random blood glucose level
After one week of receiving the HCD diet, as well as
throughout the study, the Ch Group exhibited a significant
increase in RBG compared with the C Group (p < 0.05)
(Figure 2A). However, CM administration to the ChM
Group resulted in a significant reduction in RBG in com-
parison to the Ch Group at each measurement (p < 0.05),
with no significant difference with respect to the C Group
(p > 0.05). The administration of CM to the CCM Group
Figure 2 The changes in random blood glucose level (A), fasting blood glucose, serum insulin and HOMA-IR (B) in the control and
high-fat diet treated groups and the effect of camel’s milk intake. CCM; control + milk group, Ch; cholesterol group, ChM; cholesterol + milk
group. Values are presented as the mean ± SD. † p < 0.05 versus Control, ‡ p < 0.05 versus Control + camel milk, § p < 0.05 versus Cholesterol,
¶ p < 0.05 versus Cholesterol + camel milk.
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Group (p > 0.05).Fasting blood glucose and serum insulin
Eight weeks of daily ingestion of HCD impaired the
FBG of the Ch Group as compared with the C Group
(p < 0.001) (Figure 2B). Camel milk administration inhibited
HCD-induced hyperglycemia in the ChM Group in
comparison with the Ch Group (p = 0.004), but there was
no significant difference with respect to the C Group
(p = 0.17). However, the CM-treated CCM Group rats
showed no significant change in FBG compared with
the C Group (p > 0.05). The fasting serum insulin levelincreased significantly in association with the elevated
FBG in the Ch Group compared with the control
Group (p < 0.001) (Figure 2B). This change was similar to
that observed in patients with NASH. However, CM
intake significantly decreased the fasting insulin level of the
ChM Group in comparison to the Ch Group (p < 0.001),
reaching the control level (p > 0.05). However, the fasting
insulin level of the CCM showed no significant change in
comparison with the C Group (p > 0.05) (Figure 2B).HOMA-IR
A high-fat, cholesterol-rich diet induced a significant
increase in the IR in the Ch Group animals compared
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by the high HOMA-IR. Camel milk administration to
the ChM Group decreased their HOMA-IR compared
with the Ch Group (p < 0.001), reaching the control range
(p > 0.05) (Figure 2B). Notably, the administration of CM
to the CCM Group, in addition to the normal rat chow,
resulted in no significant changes in the HOMA-IR
compared with the C Group (p > 0.05).GTT and ITT
Fasting and postprandial hyperglycemia were evident in
the Ch Group animals in comparison to the control
Group C animals at all time points of the glucose tolerance
curve (p < 0.001). The blood glucose levels in the Ch Group
reached the peak at 30 min after i.p. glucose loading
and then decreased slightly by 150 min but did not reach
the fasting level. This confirmed the glucose intolerance
(Figure 3A).Figure 3 Intraperitoneal glucose tolerance test (i.p GTT) (A), and insu
with and without camel milk treatment for 8 weeks. CCM; control + mi
are presented as the mean ± SD.In contrast, the CM-treated ChM animals showed sig-
nificant fasting hypoglycemia in comparison to Group Ch
animals (p = 0.02) and the postprandial hyperglycemia was
significantly inhibited, with lower levels of blood glucose
in comparison to the Ch Group from 0 time until 150 min
of the GTT (P < 0.05). It is worth noting that the i.p.
glucose tolerance curve in Group ChM animals was
comparable to that of Group C animals at 0, 30, 60 and
90 min (P < 0.05) (Figure 3A).
Intraperitoneal insulin injection caused significant com-
parable hypoglycemia in the C and CCM Groups during
the ITT. The Ch Group showed significant inhibition in
the response to insulin injection in comparison to the C
Group (p < 0.001). The expected hypoglycemia after intra-
peritoneal injection was significantly inhibited in the CH
Group compared to the C Group (the glycemic decay in
response to intraperitoneal ITT in the ChM Group was
significantly recovered after CM treatment as an index of
the peripheral insulin sensitivity) (Figure 3B).lin tolerance test (ITT) (B) in rats fed standard and high-fat diets
lk group, Ch; cholesterol group, ChM; cholesterol + milk group. Values
Figure 4 Lipid profile and atherogenic index in rats fed
standard and high-fat diets with and without camel milk
treatment for 8 weeks. CCM; control+ milk group, Ch; cholesterol
group, ChM; cholesterol+ milk group. Values are presented as the
mean ± SD. † p < 0.05 versus control, ‡ p < 0.05 versus CCM,
§ p < 0.05 versus Ch, ¶ p < 0.05 versus ChM.
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The level of MDA, a marker of lipid peroxidation, in-
creased significantly in the serum and livers of the Ch
Group animals compared with the C Group (p < 0.001)
(Table 1). This was associated with a significant decrease
in CAT activity and GSH levels (p < 0.001). Alternatively,
CM administration to the ChM Group reversed the oxida-
tive stress effect of HCD, as evidenced by the significant
reduction in the MDA level, the increase in CAT activity,
and the elevation of GSH levels compared with the Ch
Group (p < 0.001). The serum and liver levels of MDA,
GSH, and CAT activity were comparable in both the CCM
and C Groups (p > 0.05).
Lipid profile
The ingestion of HCD by the Ch Group animals resulted
in significant increases in TC, TG, LDL-C, and VLDL-C
and decreased the HDL-C levels compared with the C
Group animals (p < 0.001) (Figure 4). Camel milk treat-
ment in the ChM Group reversed the lipid profile changes
induced by HCD in the Ch Group (P < 0.001), reaching
the control level (p > 0.05). Interestingly, CM treatment in
the CCM Group resulted in a significant reduction in the
TC, TG, LDL-C and VLDL-C levels (p < 0.001) but caused
no significant change in the HDL-C level compared with
the C Group (p > 0.05).
The atherogenic index (AI)
In association with the hyperlipidemia and dyslipidemia
observed in the Ch Group animals, the AI was signifi-
cantly higher in comparison to the C Group (p < 0.001)
(Figure 4). Camel milk significantly decreased the AI in
the ChM Group compared with the Ch Group (p < 0.001),
reaching the control value (p > 0.05). Interestingly,
CM treatment in the CCM Group induced a signifi-
cant decrease in the AI in comparison with the CTable 1 Malondialdehyde (MDA) levels, catalase (CAT) activity
study in rats fed standard and high-fat, cholesterol-rich diets
Control (n = 10) CC
Serum MDA μM/l 0.65 ± 0.00 0.
Liver MDA μM/g tissue 1.35 ± 0.13 1.
Serum CAT activity nmol H2O2/min/mg protein 5.52 ± 1.57 4
Liver CAT activity μM H2O2/min/mg protein 60.90 ± 3.72 62
Liver GSH Mg/g tissue 22.97 ± 1.13 23
CCM; control + milk group, Ch; cholesterol group, ChM; cholesterol + milk group. Va
were identified by ANOVA test presented by F value. When significant (p value < 0.0
versus control, ‡ p < 0.05 versus CCM, § p < 0.05 versus Ch, p < 0.05 versus ChM.Group (p = 0.003). This indicates that CM had a protective
effect against atherosclerosis in the control animals.
Liver function
The administration of HCD to the Ch Group for eight
weeks resulted in significant increases in the AST, ALT,
AP, GAMA-GT, and bilirubin levels, but it decreased
the serum protein and albumin levels compared with
the C Group (p < 0.001) (Table 2). The alterations in liverand reduced glutathione (GSH) levels at the end of the
with and without camel milk treatment
M (n = 20) Ch (n = 20) ChM (n = 20) F value P value
65 ± 0.00 § 8.07 ± 1.4 †‡ 0.65 ± 0.00 § 462.02
<0.001
32 ± 0.12 § 1.95 ± 0.16 †‡ 1.59 ± 0.09†‡§ 47.93
<0.001
.96 ± 0.61§ 3.95 ± 1.04 †‡ 5.02 ± 0.73 § 17.13
<0.001
.51 ± 2.98 § 47.70 ± 3.37 †‡ 56.30 ± 2.29 †‡§ 44.78
<0.001
.11 ± 1.12 § 14.17 ± 1.38 †‡ 23.11 ± 1.08 †‡§ 131.49
<0.001
lues are presented as the mean ± SD. Significant differences between all groups
5), a post hoc LSD test was performed to compare the groups. † p < 0.05
Table 2 Liver function tests in rats fed standard and high-fat, cholesterol-rich diets with and without camel milk
treatment for 8 weeks
Control (n=10) CCM (n=20) Ch (n=20) Ch M (n=20) F value P value
AST (U/L) 45.99 ± 2.47 48.16 ± 3.08 § 57.41 ± 3.18 †‡ 50.91±4.18†‡§ 35.49
<0.001
ALT (U/L) 52.43 ± 2.69 54.76 ± 4.18 § 70.77 ± 4.19 †‡ 56.68±3.90†‡§ 79.84
<0.001
AP (U/L) 85.39 ± 6.44 83.79 ± 6.36 § 116.33 ± 6.79 †‡ 104.80 ±6.12†‡§ 105.86
<0.001
GAMA-GT (U/L) 43.47 ± 8.19 44.14 ± 6.67 § 50.12 ±5.45 †‡ 45.74 ±3.95 †§ 4.46
0.006
Total bilirubin (mg/dl) 1.45 ± 0.23 1.28 ± 0.19 § 2.07 ± 0.44 †‡ 1.23 ± 0.14 †§ 36.70
<0.001
Direct bilirubin (mg/dl) 0.43 ± 0.08 0.49 ± 0.11§ 0.82 ± 0.10 †‡ 0.46 ± 0.08 †§ 61.65
<0.001
Total proteins (mg/dl) 4.6 ± 0.19 6.25 ± 0.23 †‡ 4.17 ± 0.15 †‡ 5.05 ± 0.41 †‡§ 199.68
<0.001
Serum albumin (mg/dl) 3.45 ± 0.05 3.85 ± 0.40 †§ 3.15 ± 0.09 †‡ 3.57 ± 0.28 †‡§ 23.31<0.001
CCM; control + milk group, Ch; cholesterol group, ChM; cholesterol + milk group. Values are presented as the mean ± SD. Significant differences between all groups
were identified by ANOVA test presented by F value. When significant (p value < 0.05), a post hoc LSD test was performed to compare the groups. † p < 0.05
versus control, ‡ p < 0.05 versus CCM, § p < 0.05 versus Ch, ¶ p < 0.05 versus ChM.
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ChM Group after CM treatment (p < 0.001). Furthermore,
the CCM Group showed significant elevation of the total
serum protein and albumin levels compared with the C
Group (p < 0.001), in the absence of any changes in the
other liver function parameters (p > 0.05).Histopathology
Macroscopic examination of livers of the C and CCM
Groups (Figure 5A, B) showed a normal red, smooth,
and shiny appearance. In contrast, livers from the Ch
Group (Figure 5C) were extremely pale, enlarged, and
extensively infiltrated with white spots that reflect fat
accumulation inside the hepatic cells. The livers from
animals in the ChM Group receiving CM (Figure 5D)
were slightly pale with few scattered white spots compared
with the Ch Group. Light microscopic examination of the
liver tissue in the C and CCM Groups stained by H&E
showed normal polyhedral hepatocytes with central nuclei
and eosinophilic cytoplasm (Figure 5E, F). In contrast,
the Ch Group showed ballooning degeneration of the
hepatocytes, loss of the cytoplasmic eosin, eccentric
nuclei, diffuse microvesicular and macrovesicular steatosis
(50% grade 1, 20% grade 2 and 30% grade 3), portal in-
flammation, foci of lobular inflammation, and necrosis
(Figure 5G). Camel milk treatment in the ChM Group
markedly attenuated the histopathological characteristics
of NASH observed in the Ch Group. There was mild
microvesicular steatosis in 20% of the tissues, and steatosiswas nearly absent in the rest of the samples, with intact
architecture and no inflammatory foci (Figure 5H).
Discussion
The worldwide epidemic of obesity and diabetes is
closely associated with the increased incidence of NAFLD
[27,31]. Life style modification and the acquisition of
healthy food habits are the most clinically recognized and
effective methods to control the disease and minimize
the progression to NASH and cirrhosis [33]. In Islamic
communities, CM has gained a good reputation due to
its health benefits stated by the Prophet Mohammed
(PBUH) more than 1400 years ago [34] and to the folklore
stories detailing its shielding effects against a wide range
of diseases. Multiple recent studies have reported that
CM has antiviral, antibacterial, hypoglycemic, antihy-
pertensive, hypocholesterolemic, and anticancer activ-
ities [14,16,17,19-22].
The present study investigated the effect of CM on
the metabolic alterations in the lipid profile, glucose
homeostasis, IR, and oxidative-antioxidative balance and
the functional and structural changes of hepatocytes in
NAFLD induced by HCD. Feeding the Ch Group animals
with HCD resulted in dramatic increases in the TC, TG,
LDL-C, VLDL-C levels and in the AI, but it decreased the
HDL-C levels. This hyperlipidemia could be related to
the enhanced de-esterification of the abundant FFAs and
decreased lipoproteins [35]. The biochemical picture of
dyslipidemia in the Ch Group animals was associated with
hepatic steatosis, focal lobular inflammation, ballooning
Figure 5 Gross and microscopic changes in the liver of the control and high-fat diet groups with and without camel milk intake. Part I:
Gross macroscopic evaluation of the liver from the Control group (part A) and the control + camel milk Group (part B) showed red, smooth and
shiny liver tissues. Livers from the Cholesterol Group (part C) that received the high-fat diet for eight weeks were extremely pale, enlarged, and
extensively infiltrated with white spots that reflect fat accumulation inside the hepatic cells. The Cholesterol + milk group (part D) received camel
milk for eight weeks, and the livers showed marked improvement compared to the livers of the untreated group; the livers were slightly pale
with few scattered white spots compared with the Ch Group. Part II: 40X photomicrograph of the H and E stained liver tissue of the Control
(part E) and the Control + milk groups (part F) showing normal polyhedral hepatocytes with a central nucleus and eosinophilic cytoplasm. In
contrast, the Ch Group (part G) showed ballooning degeneration of the hepatocytes, loss of cytoplasmic eosin and eccentric nuclei, with diffuse
microvesicular and macrovesicular steatosis, and foci of lobular inflammation and necrosis. Camel milk treatment in the ChM Group (part H)
markedly attenuated the histopathological characteristics of NASH observed in the Ch Group. The ChM group showed only mild microvesicular
steatosis, no inflammatory foci, and intact architecture.
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ches the reported histopathological features of NASH [1].
In addition to hyperlipidemia, the Ch Group animals
showed enhanced oxidative stress, as evidenced by in-
creased MDA levels and decreased CAT activity and GSH
levels. This could be related to the beta-oxidation of fatty
acids in hepatic steatosis, which stimulates reactive oxygen
species (ROS) generation, lipid peroxidation, hepatocyte
necro-inflammation, and apoptosis [35]. The oxidative
stress produced by excess ROS production and decreased
antioxidant mechanisms plays an important role in the
chronic inflammatory responses to hypercholesterolemia
and is known to activate hepatic stellate cells and to
trigger fibrogenesis [36,37]. Therefore, steatosis is consid-
ered the basic event in the multi-step process of NASH,
which comes in association with increased total body fat
and visceral obesity [38].
The adipocytes are no longer considered passive cells
that store excessive triglycerides but are instead con-
sidered active cells that regulate the energy balance
and secrete the pro-inflammatory cytokines Il-6, and
TNF-α [39]. This leads to the suggestion that multipleimmunomodulatory factors and ROS contribute to the
chronic inflammatory condition and the hepatocytes
injury observed in steatohepatitis [40].
The observed loss of the structural integrity of the
hepatic tissue in the Ch Group animals demonstrated
hepatic cell injury, which led to the release of excessive
amounts of intracellular hepatic transaminases into the
serum, and the high biliary pressure augmented AP,
GAMA-GT, and bilirubin synthesis by the cells lining
the hepatic canaliculi [41]. The structural distortion and
the functional impairment of the hepatic cells by NASH
in the Ch Group were associated with hyperinsulinemia,
high IR, and low serum protein and albumin levels. These
may be related to the excessive release of adipokines
and FFAs from adipose tissue, which in turn, may induce
islet cell apoptosis and liver gluconeogenesis, both of
which contribute to IR, diabetes, and atherosclerotic
cardiovascular complications [42].
Camel milk has a unique composition that distinguishes
it from other ruminant milk. It is low in sugars, choles-
terol, and proteins but is rich in minerals (sodium, potas-
sium, iron, copper, zinc and magnesium) and vitamins (A,
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nutrients, vitamins, and trace elements, which have bio-
logical activities against several diseases [14,16,17,19-22].
The obvious amelioration of the hyperlipidemia and
dyslipidemia in the CM-treated ChM Group is in agree-
ment with recent reports about fresh and fermented CM
containing Bifidobacteria, which lower plasma lipids in rats
receiving a high-cholesterol diet [22,46]. The hypolipidemic
effect of CM could be directly related to the content of high
L-carnitine, which decreases cholesterol absorption [47,48].
However, two indirect mechanisms could also be proposed
for the improvement of the lipid profile and the decreased
body weight in the ChM Group: (i) CM may exert local
effects on the stomach to inhibit gastric emptying or
give a sense of satiety and decrease food intake. (ii)
Camel milk may alter the PPAR alpha/SREBP1 ratio, as
mentioned in recent work conducted by Ziamajidi N, et al.
[49], leading to enhanced activity of the fat-metabolizing
enzymes and hormones, resulting in increased caloric loss
or decreased fat storage.
All of the histological features of NASH observed in
the Ch Group in the present study, especially the
inflammatory foci, showed marked improvement in the
CM- treated ChM Group. This has a specific importance,
as it was recently reported that inflammation is the only
predictor of fibrosis progression and the development of
cirrhosis [50]. The high magnesium and trace element
contents in CM can protect against oxidative damage and
help the absorption and metabolism of the antioxidant
vitamins B, C, and E [45]. The antioxidant effect of CM
plays a role in the reduction of hepatic fat accumulation
and decreases systemic and hepatic oxidative stress [51],
as evidenced by increased GSH levels and CAT activity
and decreased MDA production in the ChM Group.
In addition to its specific composition, the digestion of
CM in the gastrointestinal tract produces many bioactive
compounds with antimicrobial, antioxidant, immuno-
modulatory, and hepatoprotective effects [52]. Similarly,
the healing of the hepatic parenchyma observed by
microscopic examination in the ChM Group was associated
with the recovery of normal serum proteins and albumin
levels and decreased serum transaminases, bilirubin, AP,
and GAMA-GT levels. In this regard, vitamin E treatment
was reported to decrease serum transaminases and hepatic
steatosis [53], which supports the notion that the high
vitamins and trace elements content in CM protect
hepatocytes integrity and prevents the release of trans-
aminases into the blood.
The current findings are in accordance with the similar
hepatic protective effects of CM recently reported in
carbon tetrachloride, paracetamol and alcohol toxicity
[21,54,55]. Decreased serum insulin and RBG levels
and the improved glycemic decay in response to insulin
injection in the ChM Group compared to the ChGroup reflected increased peripheral response to insulin,
as confirmed by the decreased HOMA-IR. The high
concentration of insulin (40 units/l) and insulin-like
protein and the immunoglobulin contents of CM [18,56]
identified it as a natural product that not only helps
glycemic control but also preserves the normal lipid
profile, as evidenced in the CM-treated animals in the
present study. In addition to CM, other natural products
or medicinal herbs, including chicory leaves, barely grains,
celery, Lyceum and Barbarum, have been reported to
have both glucose-lowering and lipid-lowering capabil-
ities [57,58].
This is the first study, to the best of our knowledge,
to investigate the effects of CM on the biochemical and
histological changes related to NAFLD. Camel milk
exerted multi-faceted metabolic effects in HCD-induced
NAFLD. These effects could be mostly attributed to the
active components in CM, which may act independently
or interact together in endocrine, paracrine, or autocrine
modes of action, leading to the modification of the
metabolic abnormalities of NAFLD [59]. However, one
limitation of the current study was the difficulty in spe-
cifying the active ingredients in CM that acted either
individually or through molecular interactions to produce
the observed changes in NAFLD in the treated animals.
The isolation and identification of such active components
require a detailed bio-analytical technique that was not
within the scope of the current study, but it represents an
important future research area that could be investigated
by our research group and other investigators.
Conclusions
The findings of the current study led us to conclude
that camel milk markedly improved the biochemical
and histopathological abnormalities induced by HCD,
including hyperlipidemia, steatohepatitis, impaired liver
function, and insulin resistance. These findings support
the reported health-promoting effects of CM and support
its role in treating hyperlipidemia-associated chronic health
problems resulting from unhealthy lifestyles and eating
habits. However, large-scale clinical trials with large
populations are still needed to confirm the results
obtained from animal studies.
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